Seroprevalence of hepatitis B virus infection among children and adolescents in Singapore, 2008-2010

被引:16
作者
Ang, Li Wei [1 ]
Tey, Su Hui [1 ]
Cutter, Jeffery [2 ]
James, Lyn [1 ]
Goh, Kee Tai [3 ]
机构
[1] Minist Hlth, Epidemiol & Dis Control Div, Singapore 169854, Singapore
[2] Minist Hlth, Communicable Dis Div, Singapore 169854, Singapore
[3] Minist Hlth, Off Director Med Serv, Singapore 169854, Singapore
关键词
hepatitis B surface antigen; antibody against hepatitis B surface antigen; national childhood immunization program; chronic hepatitis B virus infection; UNITED-STATES; IMMUNIZATION PROGRAM; VACCINE; IMMUNOGENICITY; TRANSMISSION; PREVALENCE; ENGLAND; ADULTS;
D O I
10.1002/jmv.23496
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A national pediatric survey was undertaken to determine the prevalence of hepatitis B virus markers in Singapore. The aim was to assess the impact of the national childhood immunization program against hepatitis B implemented for all newborns since 1987. The survey involved prospective collection of residual sera from Singapore residents aged 117 years attending inpatient services or day surgery in two public hospitals between August 2008 and July 2010. A total of 1,200 sera were collected comprising 400 in each of the three age groups of 16, 712, and 1317 years. The sera were tested for hepatitis B surface antigen (HBsAg) and antibody to HBsAg (anti-HBs). Four of the 1,200 samples tested positive for HBsAg, giving an overall prevalence of 0.3%. One and three in the 712 years and 1317 years age groups, respectively, were positive for HBsAg. About 40% possessed anti-HBs (10mIU/ml); the antibody prevalence decreased significantly from 63.8% in children aged 16 years to 32.8% in 712 year olds, and 23.5% in 1317 year olds (P<0.0005). The successful implementation of the national childhood hepatitis B immunization program over the last two decades has resulted in a low prevalence of HBsAg among children and adolescents. Singapore has achieved the World Health Organization Western Pacific Region's goal in reducing the prevalence of chronic HBV infection to below 2% among children aged 5 years and older by 2012 and to below 1% by 2017. J. Med. Virol. 85:583588, 2013. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:583 / 588
页数:6
相关论文
共 37 条
  • [21] 4-YEAR EXPERIENCE WITH A RECOMBINANT HEPATITIS-B VACCINE
    JILG, W
    SCHMIDT, M
    DEINHARDT, F
    [J]. INFECTION, 1989, 17 (02) : 70 - 76
  • [22] Hepatitis B and the Need for a Booster Dose
    Leuridan, Elke
    Van Damme, Pierre
    [J]. CLINICAL INFECTIOUS DISEASES, 2011, 53 (01) : 68 - 75
  • [23] Epidemiological serosurvey of Hepatitis B in China-Declining HBV prevalence due to Hepatitis B vaccination
    Liang, Xiaofeng
    Bi, Shengli
    Yang, Weizhong
    Wang, Longde
    Cui, Gang
    Cui, Fuqiang
    Zhang, Yong
    Liu, Jianhua
    Gong, Xiaohong
    Chen, Yuansheng
    Wang, Fuzhen
    Zheng, Hui
    Wang, Feng
    Guo, Jing
    Jia, Zhiyuan
    Ma, Jingchen
    Wang, Huaqing
    Luo, Huiming
    Li, Li
    Jin, Shuigao
    Hadler, Stephen C.
    Wang, Yu
    [J]. VACCINE, 2009, 27 (47) : 6550 - 6557
  • [24] Liew F, 2010, ANN ACAD MED SINGAP, V39, P532
  • [25] Mast Eric E., 2006, Morbidity and Mortality Weekly Report, V55, P1
  • [26] Ministry of Health Singapore, 2011, COMM DIS SURV SING 2
  • [27] Nelson CB, 2002, WHO REG OFF W PAC WO
  • [28] O'Sullivan BG, 2004, AUST NZ J PUBL HEAL, V28, P212, DOI 10.1111/j.1467-842X.2004.tb00697.x
  • [29] Ten years of serological surveillance in England and Wales: methods, results, implications and action
    Osborne, K
    Gay, N
    Hesketh, L
    Morgan-Capner, P
    Miller, E
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2000, 29 (02) : 362 - 368
  • [30] Plotkin S.A., 2013, Vaccines, VSixth